

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

INTEGRAMED AMERICA INC
Form 10-Q
May 15, 2002

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 0-20260

IntegraMed America, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

06-1150326

(State or other jurisdiction of
incorporation or organization)

(I.R.S. employer identification no.)

One Manhattanville Road
Purchase, New York

10577

(Address of principal executive offices)

(Zip code)

(914) 253-8000

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

The aggregate number of shares of the Registrant's Common Stock, \$.01 par value, outstanding on April 23, 2002 was 3,085,516.

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

INTEGRAMED AMERICA, INC.
FORM 10-Q

TABLE OF CONTENTS

	PAGE
PART I - FINANCIAL INFORMATION	
Item 1. Financial Statements	
Consolidated Balance Sheets at March 31, 2002 (unaudited) and December 31, 2001.....	3
Consolidated Statements of Income for the three-month periods ended March 31, 2002 and 2001 (unaudited).....	4
Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2002 and 2001 (unaudited).....	5
Notes to Consolidated Financial Statements (unaudited).....	6-7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	8-12
Item 3. Quantitative and Qualitative Disclosures About Market Risk.....	12
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings.....	13
Item 2. Changes in Securities.....	13
Item 3. Defaults upon Senior Securities.....	13
Item 4. Submission of Matters to a Vote of Security Holders.....	13
Item 5. Other Information.....	13
Item 6. Exhibits and Reports on Form 8-K.....	13
SIGNATURES	14

PART I -- FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

INTEGRAMED AMERICA, INC.
CONSOLIDATED BALANCE SHEETS
(all dollars in thousands, except per share amounts)

ASSETS

	March 31	Dece
	2002	
	(unaudited)	
Current assets:		
Cash and cash equivalents	\$ 9,278	\$
Due from Medical Practices, net	4,522	
Pharmaceutical sales accounts receivable	2,864	
Prepays and other current assets	1,743	
	-----	-----
Total current assets	18,407	1
Fixed assets, net	5,391	
Intangible assets, net	17,503	1
Deferred taxes	4,652	
Other assets	239	
	-----	-----
Total assets	\$ 46,192	\$ 4
	=====	=====

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:		
Accounts payable	\$ 1,938	\$
Accrued liabilities	4,976	
Current portion of long-term notes payable and other obligations	1,332	
Patient deposits	5,938	
	-----	-----
Total current liabilities	14,184	1
	-----	-----
Long-term notes payable and other obligations	1,000	
	-----	-----
Shareholders' equity:		
Preferred Stock, \$1.00 par value - 3,165,644 shares authorized in 2002 and 2001, 2,500,000 undesignated; 665,644 shares designated as Series A Cumulative Convertible of which 165,644 shares were issued and outstanding in 2002 and 2001, respectively	166	
Common Stock, \$.01 par value - 50,000,000 shares authorized in 2002 and 2001; and 3,080,516 and 3,057,877 shares issued in 2002 and 2001, respectively ..	31	
Capital in excess of par	47,320	4
Accumulated deficit	(16,509)	(1
	-----	-----
Total shareholders' equity	31,008	3
	-----	-----
Total liabilities and shareholders' equity	\$ 46,192	\$ 4
	=====	=====

See accompanying notes to the consolidated financial statements.

INTEGRAMED AMERICA, INC.
 CONSOLIDATED STATEMENTS OF INCOME
 (all amounts in thousands, except per share amounts)

	F three-m ended ----- 2002 ----- (un
Revenues, net	
Reproductive Science Center service fees (including termination payment of \$360,000 in first quarter 2001)	\$ 15,82
Pharmaceutical sales	4,22
Other revenues	23
Total revenues	20,27 -----
Cost of services and sales:	
Reproductive Science Center costs	13,59
Pharmaceutical costs	4,05
Other costs	12
Total costs of services and sales	17,77 -----
Contribution:	
Reproductive Science Center contribution	2,23
Pharmaceutical contribution	16
Other contribution	11
Total contribution	2,50 -----
General and administrative expenses	1,80
Amortization of intangible assets	22
Interest income	(3
Interest expense	3
Total other expenses	2,02 -----
Income before income taxes	47
Income tax provision	18
Net income	\$ 29
Less: Dividends paid and/or accrued on Preferred Stock	(3
Net income applicable to Common Stock	\$ 25 =====
Basic and diluted earnings per share of Common Stock:	\$ 0.0

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

Weighted average shares - basic	3,06
Weighted average shares - diluted	3,24

See accompanying notes to the consolidated financial statements.

-4-

INTEGRAMED AMERICA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(all amounts in thousands)

	For three-mo- ended
	----- 2002 ----- (una
Cash flows from operating activities:	
Net income	\$ 291
Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation and amortization	635
Change in assets and liabilities--	
Decrease (increase) in assets:	
Due from Medical Practices	427
Pharmaceutical sales accounts receivable	(1,353)
Business Services fees receivable	--
Prepays and other current assets	218
Other assets	163
Increase (decrease) in liabilities:	
Accounts payable	502
Accrued liabilities	(117)
Patient deposits	1,287
Net cash provided by operating activities	2,053
Cash flows used in investing activities:	
Payment for exclusive Business Service rights	(350)
Purchase of fixed assets and leasehold improvements	(538)
Net cash used in investing activities	(888)
Cash flows used in financing activities:	
Principal repayments on debt	(324)
Principal repayments under capital lease obligations	(35)
Repurchase of Common Stock	--

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

Proceeds from exercise of Common Stock Warrants	---
Dividends paid on Convertible Preferred Stock	(33)

Net cash used in financing activities	(392)

Net increase (decrease) in cash	\$ 773
Cash at beginning of period	8,505

Cash at end of period	\$ 9,278
	=====

See accompanying notes to the consolidated financial statements.

-5-

INTEGRAMED AMERICA, INC.
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (unaudited)

NOTE 1 -- INTERIM RESULTS:

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, accordingly, do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position at March 31, 2002, and the results of operations and cash flows for the interim period presented. Operating results for the interim period are not necessarily indicative of results that may be expected for the year ending December 31, 2002. These financial statements should be read in conjunction with the financial statements and notes thereto included in IntegraMed America's (the "Company") Annual Report on Form 10-K for the year ended December 31, 2001.

NOTE 2 -- EARNINGS PER SHARE:

The reconciliation of the numerators and denominators of the basic and diluted EPS from continuing operations computations for the three-month periods ended March 31, 2002 and 2001 is as follows (000's omitted, except for per share amounts):

	For the three-month period ended March 31,	
	----- 2002	2001 -----
Numerator		
Net Income	\$ 291	\$ 359
Less: Preferred stock dividends	33	33
	-----	-----
Income applicable to Common Stock	\$ 258	\$ 326

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

	=====	=====
Denominator		
Weighted average shares outstanding	3,061	3,223
Effect of dilutive options and warrants	184	8
	-----	-----
Weighted average shares and dilutive potential		
Common shares	3,245	3,231
	=====	=====
Basic and diluted EPS	\$ 0.08	\$ 0.10
	=====	=====

For the three-month period ended March 31, 2002, the effect of the assumed exercise of options to purchase approximately 235,000 shares of Common Stock at exercise prices ranging from \$5.38 to \$5.98 per share and warrants to purchase approximately 25,000 shares of Common Stock at exercise prices ranging from \$5.13 to \$7.24 per share were excluded in computing the diluted per share amount because the exercise prices of the options and warrants were greater than the average market price of the shares of Common Stock, therefore causing these options and warrants to be antidilutive. For the three-month period ended March 31, 2001, the effect of the assumed exercise of options to purchase approximately 489,000 shares of common stock at exercises prices ranging from \$3.00 to \$5.00 per share and warrants to purchase approximately 103,000 shares of common stock at exercise prices ranging from \$4.12 to 8.54 per share were excluded in computing the diluted per share amount because the exercise prices of the options and warrants were greater than the average market price of the shares of common stock, therefore causing these options and warrants to be antidilutive.

-6-

INTEGRAMED AMERICA, INC.
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (unaudited)

For the three-month periods ended March 31, 2002 and 2001, approximately 136,000 and 133,000 shares, respectively, of Common Stock from the assumed conversion of Preferred Stock were excluded in computing the diluted per share amount as they were antidilutive.

NOTE 3 -- SEGMENT INFORMATION:

The Company is principally engaged in providing products and services to the fertility market. For disclosure purposes, the Company recognizes Business Services offered to its network of Reproductive Science Centers and its pharmaceutical distribution operations as separate reporting segments. The Business Services segment includes revenues and costs categorized as Reproductive Science Center Service Fees and Other Revenue, as follows (000's omitted):

	Corporate	Business Services
	-----	-----

For the three months ended March 31, 2002

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

Revenues	\$ --	\$ 16,056
Cost of services	--	13,713
	-----	-----
Contribution	--	2,343
	-----	-----
General and administrative costs	1,803	--
Amortization of intangibles	1	224
Interest, net	(1)	3
	-----	-----
Income before income taxes	\$ (1,803)	\$ 2,116
	=====	=====
Depreciation expense included above	\$ 68	\$ 342
Capital expenditures	\$ 95	\$ 443
Total assets	\$ 5,557	\$ 37,859
For the three months ended March 31, 2001		
Revenues	\$ --	\$ 13,030
Cost of services	--	10,821
	-----	-----
Contribution	--	2,209
General and administrative costs	1,689	--
Amortization of intangibles	1	213
Interest, net	44	(11)
	-----	-----
Income (loss) before income taxes	\$ (1,734)	\$ 2,007
	=====	=====
Depreciation expense included above	\$ 106	\$ 274
Capital expenditures	\$ 57	\$ 720
Total assets at December 31, 2000	\$ (868)	\$ 39,376

NOTE 4 -- SUBSEQUENT EVENT:

Subsequent to March 31, 2002, the Company signed an agreement to supply a complete range of business, marketing and facility services to the Margate, Florida-based Northwest Center for Infertility and Reproductive Endocrinology ("NCIRE"). Under the terms of the 15-year agreement, the Company's service fees will be comprised of reimbursed costs of services and a fixed percentage of revenues, plus an additional fixed percentage of NCIRE earnings. The Company has committed up to \$2 million to fund the development and equipping of a new state-of-the-art facility to house the clinical practice and embryology laboratory for NCIRE and its patients.

-7-

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes thereto included in this quarterly report and with the Company's Annual Report on Form 10-K for the year ended December 31, 2001.

IntegraMed America, Inc. (the "Company") offers products and services to patients, providers, payors and pharmaceutical manufacturers in the fertility industry. The IntegraMed Network is comprised of fourteen fertility centers in

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

major markets across the United States, a pharmaceutical distribution subsidiary, a financing subsidiary, the Council of Physicians and Scientists, and a leading fertility portal (www.integrated.com). Nine of these fertility centers have access to the Company's FertilityDirect Program. Five of the fertility centers are designated as "Reproductive Science Centers(R)" and as such, have access to the Company's FertilityDirect Program in addition to being provided with a full range of services including: (i) administrative services, including accounting and finance, human resource functions, and purchasing of supplies and equipment; (ii) access to capital; (iii) marketing and sales; (iv) integrated information systems; and (v) assistance in identifying best clinical practices (collectively, "Business Services").

The Company's strategy is to align information, technology and finance for the benefit of fertility patients, providers, payors and pharmaceutical manufacturers. The primary elements of the Company's strategy include: (i) selling additional FertilityDirect contracts to leading fertility centers in major markets; (ii) selling Shared Risk Refund Treatment Packages to patients of contracted fertility centers and managing the risk associated with the programs; (iii) selling additional Reproductive Science Center Business Service contracts; (iv) increasing revenues at Reproductive Science Centers; (v) increasing sales of pharmaceutical products and services; (vi) expanding clinical research opportunities; and (vii) establishing Internet-based access to patient-specific information on treatment process and outcomes.

In December 2000, the Company's agreement with the medical center based Reproductive Science Center was terminated early. The Company received \$1.44 million in liquidated damages pursuant to an early termination agreement. The amount received was recorded as deferred revenue at December 31, 2000, as the Company has certain transition obligations through December 2001, and accordingly was amortized ratably into income in 2001; \$360,000 in the first quarter of 2001. The cost of the transition obligations incurred was minor.

During 2001 the Company negotiated revised fee structures on all five of its major Reproductive Science Center Business Services Contracts. On four of these contracts in which Service Fees are comprised of (a) a fixed percentage of revenue, (b) a fixed percentage of medical practice earnings and (c) reimbursed cost of services, the Company negotiated lower fixed percentages on the revenue and medical practice earnings components. These lower fees are to be phased in over an estimated five-year period. The Company believes that this revised fee structure will be more than offset by growth in the underlying Medical Practice, and will in turn result in growth in the Company's aggregate revenues. On the remaining Reproductive Science Center contract, the Company negotiated higher Service Fees, which are assessed at a fixed amount each month independent of the Medical Practice's underlying revenue or earnings. In addition, as the Company implements its change in strategy to become more of a marketing-oriented rather than a service-based company, costs of implementation may be incurred prior to achieving related revenues. As a result of these issues, future income levels may be based on income streams not necessarily reflective of those experienced during 2001 or the first quarter of 2002.

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

The following table shows the percentage of revenues represented by various expense and other income items reflected in the Company's Consolidated Statement of Operations.

	For the three-month period ended March 31,	
	2002	2001
	----- (unaudited)	
Revenues, net		
Reproductive Science Center Fees	78.1%	78.9%
Pharmaceutical Sales	20.8%	21.0%
Other Revenues	1.1%	0.1%
	-----	-----
Total Revenues	100.0%	100.0%
Costs of services incurred:		
Reproductive Science Center costs	67.0%	65.4%
Pharmaceutical costs	20.0%	20.2%
Other costs	0.6%	0.2%
	-----	-----
Total Costs of services and sales	87.6%	85.8%
Contribution		
Reproductive Science Center contribution	11.1%	13.5%
Pharmaceutical contribution	0.8%	0.8%
Other contribution	0.5%	(0.1)%
	-----	-----
Total contribution	12.4%	14.2%
General and administrative expenses	8.9%	10.2%
Amortization of intangible assets	1.1%	1.3%
Interest income	(0.2%)	(0.3%)
Interest expense	0.2%	0.5%
	-----	-----
Total other expenses	10.0%	11.7%
	-----	-----
Income before income taxes	2.4%	2.5%
Provision for income taxes	1.0%	0.3%
	-----	-----
Net income	1.4%	2.2%
	=====	=====

Three Months Ended March 31, 2002 Compared to Three Months Ended March 31, 2001

Revenues, net for the three months ended March 31, 2002 were approximately \$20.3 million as compared to approximately \$16.5 million for the same period in 2001, an increase of 23.0%. Revenues for the Company's Reproductive Science Centers increased \$2.8 million, or 21.6%, from the first quarter of 2001 to the first quarter of 2002. This increase is attributed to increased patient volume at the various network sites, facilitated in part by the establishment of additional clinical locations at the Company's Boston location during the fourth quarter of 2001. Revenues for the Company's pharmaceutical division increased \$759,000, or 21.9%, from the first quarter of 2001 to the first quarter of 2002. This increase is due to increased participation within the Company's Reproductive Science Centers. Other revenues increased from \$21,000 to \$231,000 from the first quarter of 2001 to the first quarter of 2002, as a result of the rising revenue stream from the Company's FertilityDirect program.

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

Total costs of services as a percentage of revenues increased by 1.8% to 87.6% during the first quarter of 2002 as compared to 85.8% for the first quarter of 2001. Costs of services as a percentage of revenue for the Company's Reproductive Science Center division increased from 65.4% in the first quarter of 2001 to 67.0% during the first quarter of 2002. This increase is attributed

-9-

to program expansion at several network sites. Costs of services as a percentage of revenue for the Company's pharmaceutical division remained stable, decreasing 0.2% from 20.2% in the first quarter of 2001 to 20.0% in the first quarter of 2002. Other costs of services as a percentage of revenue increased from 0.2% in the first quarter of 2001 to 0.6% during the first quarter of 2002, an increase of 0.4%. This is reflective of the growth of the Company's FertilityDirect program.

Total Contribution for the first three months ended March 31, 2002 was \$2.5 million as compared to \$2.3 million for the first quarter of 2001, an increase of 6.7%.

General and administrative expenses for the first quarter of 2002 were approximately \$1.8 million as compared to approximately \$1.7 million in the first quarter of 2001, an increase of 6.7%. The increase was largely due to increases in staffing and compensation attributable to implementation of initiatives related to the Company's development of a marketing orientation strategy. As a percentage of revenues, general and administrative expenses decreased to approximately 8.9% in the first quarter of 2002 from approximately 10.2% in the first quarter of 2001.

Amortization of intangible assets was \$225,000 in the first quarter of 2002 as compared to \$216,000 in the first quarter of 2001, an increase of 4.2%. This increase was attributable to the payment of additional performance based business service fees.

Interest income for the first quarter of 2002 decreased to \$38,000 from \$54,000 for the first quarter of 2001 due to lower interest rates earned on invested cash balances. Interest expense for the first quarter of 2002 decreased to \$38,000 from \$86,000 in the first quarter of 2001 due to scheduled payments of debt on the Company's line of credit.

During the fourth quarter of 2001, the Company reduced its deferred tax asset valuation allowance as the Company had achieved a sustained level of profitability over an appropriate period and due to the likelihood of the realization of these tax assets. As such, the Company's effective tax rate for the first quarter of 2001 was approximately 12.4% and was comprised mainly of a provision for state income taxes. The effective tax rate for the first quarter of 2002 was approximately 39% and included an approximate 9% provision for state income taxes and an approximate 30% provision for the amortization of the deferred federal tax asset.

Net income was \$291,000 in the first quarter of 2002 as compared to \$359,000 in the first quarter of 2001, a decrease of 18.9%. This decrease resulted from the factors discussed above, including the amortization of the deferred federal tax asset.

Liquidity and Capital Resources

Historically, the Company has financed its operations primarily through sales of equity securities, issuance of notes and internally generated sources.

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

In addition, the Company has also commenced using bank financing for working capital and business development purposes. As of March 31, 2002, the Company had working capital of approximately \$4.2 million, unchanged from December 31, 2001.

In September 2001, the Company amended its existing credit facility with Fleet Bank, N.A. The amended facility is comprised of a \$7.0 million three-year working capital revolver, and a continuance of the Company's existing \$4.0 million 5.5 year term loan, of which approximately \$2.8 million remained outstanding with a remaining term of approximately 2.5 years as of the date of the amendment. Availability of borrowings under the working capital revolver are based on eligible accounts receivable as defined and as of March 31, 2002, the full amount of the \$7.0 million was available. As of March 31, 2002, the term loan balance was \$1.0 million. The Fleet credit facility is collateralized by all of the Company's assets.

-10-

The following summarizes the Company's contractual obligations and other commercial commitments at March 31, 2002, and the effect such obligations are expected to have on its liquidity and cash flows in future periods.

Significant Accounting Contractual Obligations and Other Commercial Commitments:

	Total	Payments Due by Period		
		Less than 1 year	1 - 3 years	
	-----	-----	-----	-----
Long-term debt.....	\$ 2,332,000	\$1,332,000	\$1,000,000	\$
Capital lease obligations.....	194,000	156,000	38,000	
Operating leases.....	14,490,000	3,208,000	8,517,000	
Total contractual and case obligations.....	\$ 17,016,000	\$4,696,000	\$9,555,000	

	Total	Amount of Commitment Expiration P		
		Less than 1 year	1 - 3 years	
	-----	-----	-----	-----
Lines of credit.....	\$ 7,000,000	\$ --	\$7,000,000	
Total commercial commitments.....	\$ 7,000,000	\$ --	\$7,000,000	

The Company also has commitments to provide accounts receivable financing to the Reproductive Science Centers in accordance with its Business Services agreements. The Company's financing of the Medical Practice's Accounts Receivable occurs monthly on the 15th of the month following generation of the receivable. The priority of repayment by the Medical Practice is the reimbursement of expenses incurred by the Company on their behalf, the fixed

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

portion of the Business Services fee and finally the variable portion of the Business Services fee. The Company is responsible for the collection of receivables, which are financed with full recourse. The Company has continuously funded these needs from cash flow from operations and the collection of the prior month's receivables. If delays in repayment are incurred, which have not as yet been encountered, the Company could draw on its existing working capital line of credit. The Company does not as a general course make advances to the Medical Practices other than for the payment of expenses on behalf of the Medical Practice for which the Company is reimbursed in the short-term. The Company has no other funding commitments to the Medical Practices.

From time to time, the Company also reviews various options concerning the possibility of raising additional long-term financing through the sale of equity or debt securities in order to fund acquisitions or construct additional medical practice facilities. These reviews are conducted as part of the ongoing management of the Company and are not necessarily tied to any specific acquisition or construction plans.

Forward Looking Statements

This Form 10-Q and discussions and/or announcements made by or on behalf of the Company, contain certain forward-looking statements regarding events and/or anticipated results within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the attainment of which involve various risks and uncertainties. Forward-looking statements may be identified by the use of forward-looking terminology such as, "may", "will", "expect", "believe", "estimate", "anticipate", "continue", or similar terms, variations of those terms or the negative of those terms. The

-11-

Company's actual results may differ materially from those described in these forward-looking statements due to the following factors: the Company's ability to acquire additional business service agreements, including the Company's ability to raise additional debt and/or equity capital to finance future growth, the loss of significant business service agreement(s), the profitability or lack thereof at Reproductive Science Centers serviced by the Company, increases in overhead due to expansion, the exclusion of infertility and ART services from insurance coverage, government laws and regulations regarding health care, changes in managed care contracting, the timely development of and acceptance of new infertility, ART and/or genetic technologies and techniques.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

-12-

Part II - OTHER INFORMATION

Item 1. Legal Proceedings.
None; no material developments in previously reported matters.

Item 2. Changes in Securities.
None.

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

- Item 3. Defaults Upon Senior Securities.
None.
- Item 4. Submission of Matters to Vote of Security Holders.
None.
- Item 5. Other Information.
None.
- Item 6. Exhibits and Reports on Form 8-K.
See Index to Exhibits on Page 15.

-13-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRAMED AMERICA, INC.
(Registrant)

Date: May 15, 2002

By: /s/ John W. Hlywak, Jr

John W. Hlywak, Jr.
Senior Vice President and
Chief Financial Officer
(Principal Financial and
Accounting Officer)

-14-

Exhibit		Number Exhibit
-----		-----
10.118	--	Service Agreement between IntegraMed America, Inc. and Northwest Center for Infertility and Reproductive Endocrinology dated April 26, 2002.
99.8	--	Registrant's Press Release dated January 29, 2002 (1)
99.9	--	Registrant's Press Release dated February 14, 2002 (2)
99.10	--	Registrant's Press Release dated February 21, 2002 (3)
99.11	--	Registrant's Press Release dated March 25, 2002 (4)
99.12	--	Registrant's Press Release dated May 2, 2002 (5)

Edgar Filing: INTEGRAMED AMERICA INC - Form 10-Q

99.13 -- Registrant's Press Release dated May 9, 2002 (6)

- (1) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated January 29, 2002
- (2) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated February 14, 2002
- (3) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated February 21, 2002
- (4) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated March 25, 2002.
- (5) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated May 3, 2002.
- (6) Filed as exhibit with identical exhibit number to Registrant's Report on Form 8-K dated May 10, 2002.